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EXPLANATORY  MEMORANDUM  AND  REPORT  TO  THE  COUNCIL 
GENERAL  CONSIDERATIONS 
commission  proposals  for  three of  the  legislative measures 
Identified  In  the  1985  White  Paper  as  being  necessary  for  the 
completion of  the  Internal  Market  In  the  pharmaceutical  sector 
remain  outstanding.  The  first  of  these  three  proposals,  "the 
completion of  work  eliminating obstacles  to  the  tree circulation of 
pharmaceutical  products",  relates  to  the  wholesale  distribution of 
medicinal  products. 
In  addition,  the  White  Paper  refers  to  two  further  measures  which 
were  Initially scheduled  for  presentation  to  the  Council  In  1990, 
namely: 
harmonization of  conditions of  distribution  to  patients; 
Information of  doctors  and  patients. 
2  Following  the  entry  Into  force  of  the  Single  European  Act,  and  In 
particular  the  Introduction of  the  Cooperation  Procedure with  the 
European  Pari lament,  It  has  become  apparant  that  the  presentation of 
these proposals  In  1990 wll I  allow  very  1 lttle time  for  their 
discussion  by  the  European  Pari lament  and  the  Councl I  and  their 
Implementation  by  Member  States before  1  January  1993.  For  this 
reason  the  Commission  has  decided  that  al 1 outstanding  White  Paper 
proposals  should  be  submitted  to  the  Councl 1. 
3  The  references  to  the  three  proposals on  the  rational  use of 
medicines  were  del lberately  Included  at  the  end  of  the  White  Paper 
programme  In  order  to enable  the  services of  the  Commission  to  take 
Into account  the  progress  achieved  during  the  earlier  stages of  the 
Implementation of  the White  Paper  programme.  This  lnc~ud~s not  only 
the  removal  of  technical  barriers  to  the  free  movement  of  medicinal 
products  resulting  from  different  national  requirements  on  the 
provision of  Information  on  or  In  the  packaging  of  medicinal 
products,  but  also  the  removal  of  physical  barriers  to  the  tree 
movement  of  persons  who  may  wish  to  take  their  medication with  them 
or  obtain certain medication  trom  other  Member  States  and  other 
aspects connected with  the  realization ot  a  "Citizens'  Europe". :~ ....  ~ 
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I I  CONTROLS  ON  THE  WHOLESALE  DISTRIBUTION 
4  Traditionally,  the distribution systems  for  pharmaceuticals  within 
Member  States  have  been  organised  along  national  I lnes with 
relatively simple  structures;  manufacturers,  wholesalers,  retailers. 
Cross  frontier  distribution systems  have  been  rare.  As  the  Community 
further  progresses  towards  the  real lzatlon of  the  Internal  market, 
this situation  Is  I lkely  to  change;  Indeed  It  Is  already  beginning 
to  do  so.  First  there  Is  the  phenomen  of  paral lei  Imports.  Secondly, 
It  Is  possible  that  after  1992,  transfrontler  distribution  systems 
wll I  emerge.  In  cases 87  and  88/85,  Legla et  al.  v;  Luxembourg, 
Judgement  of  27  May  1986,  the  Court  of  Justice  ruled  that  a  Member 
State may  not  prevent  a  wholesaler  establ !shed  In  another  Member 
State  from  directly supplying  pharmacies  In  Its  territory. 
5  The  development  of  such  arrangements  may  present  several  problems 
for  the  Member  States.  First,  they  will  Inevitably make  the 
operation of  the  traditional  supervision of  the  distribution system 
and  the operation of  the  batch  recal I  system  more  difficult.  Second, 
It  may  be  difficult  for  the  authorities,  or  customers,  to  check  on 
the  status of  suppl lers  from  other  Member  States.  Third,  such  new 
arrangements  may  threaten security of  supply  and  the  capacity of 
the distribution  system  to supply  medicinal  products  rapidly  to 
patients. 
6  Following  the  Commission's  recent  proposals  to  Introduce  certain 
controls on  distribution  Into  the  directives  relating to veterinary 
medicinal  products  (COM  (88)  779),  It  Is  therefore necessary  to 
Introduce  further  controls  In  relation  to  the  distribution of 
medicinal  products  for  human  use. 
/ ·  .. 
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7  In  principle,  there  should  be  only  three  types  of  person  Involved  In 
the distribution of  medicinal  products;  manufacturers,  wholesalers, 
and  retailers.  Any  person  who  deals  In  a  medicinal  product  within 
the  territory of  the·Communtty,  but  does  not  manufacture  It  and  who 
Is  not  permitted  to sell  It  to  the  publ lc  should  be  asslml lated  to  a 
wholesaler.  This  would  cover  para! let  Importers,  and  other 
Intermediate  dealers,  Including  persons  holding  medicinal  products 
In  stock  for  export.  In  addition,  of  course,  wholesalers  who 
undertake  any  manufacturing operation,  lncludtng  ie-packaglng, 
reQuire  a  manufacturing authorization  In  accordance  with  Directive 
75/319/EEC. 
8  A specific authorization  for  wholesalers  should  be  Introduced  Into 
the  legislation,  to  be  reQuired  In  each  Member  State  In  which  the 
wholesaler  has  storage fact titles.  The  granting of  such  an 
authorization should  be  dependant  upon  the  wholesaler  having 
suitable premises,  to be  verified  by  Inspection,  having  available 
the  services of  a  Qualified person  and  maintaining  adequate 
distribution  records.  The  record-keeping  requirement  may  also be 
necessary  for  manufacturers,  and  to  the  extent  necessary,  for  retail 
pharmacists. l.~ .'·  l 
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II I  "HARMONIZATION  OF  CONDITIONS  OF  DISTRIBUTION  TO  PATIENTS" 
9  Medicines  for  self-medication are  sold prlmarl ly  with  the  Intention 
that  they  be  used  by  consumers  on  their  own  responslbl 1 lty when  they 
consider  such  use  appropriate.  The  package  size,  labelling  and 
leaflet  wl  II  generally  be  chosen  with  this  purpose  in  view,  and  In 
many  countries  these medicines,  which  are  also often referred  to as 
over  the  counter  medicines  (OTCs),  may  also  be  promoted  to  the 
general  public.  Nevertheless,  there  Is  a  large  group of  products 
which  can  only  be  obtained on  prescrlptlqn  from  a  health 
profess lena I. 
10  In  the opinion of  the  Commission,  persons  moving  within  the 
Community  have  a  right  to bring  with  them  reasonable  quantities of 
medicinal  products  lawfully obtained  for  their  own  personal  use.  A 
recent  judgement  of  the Court  of  Justice suggests  that  this  right 
may  exist  not  only  In  the  case of  medicinal  products  which  are 
carried with  a  person,  but  also  that  In  certain circumstances  a 
person  may  be  able  to  Import  by  post  reasonable quantities of  a 
medicinal  product  which  Is obtained  lawfully  In  another  Member  State 
for  his  personal  use  (Case  215/87,  Schumacher,  judgement  of 7  March 
1989). 
11  In  order  to facilitate  the exercise of  these  rights  and  to  provide 
member  States with  a  guarantee  against  any  abuse,  the  Commission 
con~.lders  that  urgent  consideration should  be  given  to  the 
harmonization of  the criteria to  be  used  In  future  In  order  to 
classify medicines  as  prescription only  (legal  status  for  the  supply 
of  medicinal  products). 
Reference  should  be  made,  In  this  aspect,  to  the  United  Nations 
Conventions  on  narcotic  and  psychotropic  drugs. 
In  addltloni medicines  which  should only  be  aval lable·on 
prescription are  the subject  of  a  Councl I  of  Europe  Resolution  AP 
(88)  2,  which  Is  already  accepted  by  10 Member  States;  Belgium, 
Denmark,  Spain,  Germany,  France,  Ireland,  Italy,  Luxembourg,  the 
Netherlands  and  the  United  Kingdom. 
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12  The  following  criteria. whoch  would  appear  to  cover  those  most 
commonly  used  by  the  Member  States when  they  authorize  the  marketing 
of  products,  are  prop~sed for  consideration: 
the  nature  of  the  product,  Including  Its  toxicity,  the 
Indications  for  which  It  Is  presented,  precautions,  warnings  and 
contra-Indications,  tolerance  and  dependancy,  Inter-actions  and 
potential lzatlon. 
the  need  for  cl lnlcal  diagnosis 
the  need  for  special  Instruction  for  the  patient 
parenteral  use 
the  novelty  of  the  product. 
IV  INFORMATION  FOR  PATIENTS 
13  Before  discussing  In  detail  the  various measures  proposed  under  this 
heading,  It  Is  maybe  useful  to  consider  briefly  the  role of  the 
Community  In  respect  of  the  regulation of  the  provision of 
Information  about  medicinal  products.  It  Is  clear  that  differences 
In  the  requirements  on  the  Information  Included  with  a  medicinal 
product  (labels,  package  Inserts)  may  create  a  barrier  to  the  free 
movement  of  the  medicinal  products  concerned.  As  a  result  of  the 
consultations which  have  been  held  so  far,  the  Commission  has  come 
to  the conclusion  that,  as  a  general  principle,  the  Information 
provided on  or  In  the  packaging of  a  medicinal  product  In  Its  final 
sales presentation should  be  exclusively  addressed  to  the  user  of 
the  product.  The  Inclusion of  Information  Intended  exclusively  for 
the doctor  no  longer  appears  appropriate. 
14  However,  the  role of  the  Community  on  the  Information  about 
medicines  Is  not  limited  to  Information  which  Is  actually  Included 
with  the  medicinal  product.  Since  the  adoption  of  the misleading 
advertlsln~dlrectlve (Directive 84/450/EEC,  O.J.  N°  L  250,  19.9.84, 
p.  17)  It  has  been  recognised  that  the  Community  has  a  role  In 
ensuring  that  the  deceptive  advertising of  products  does  affect  the 
economic  behaviour  of  the  persons  to  whom  It  Is  addressed  In  a 
manner  which  may  be  harmful  to  the  economic  Interests of  a 
competItor. - 8  -
In  an  area  as  complex  as  the  control  of  the  provision of  Information 
about  medicinal  products,  It  Is  difficult  to  draw  rigid distinctions 
between  economic  and  publ lc  health  considerations.  The  question of 
pharmaceutical  advertising  Is  under  consideration  In  the  services of 
the  Commission. 
15  As  far  as  factual  Information  about  medicinal  products  Is  concerned, 
a  special  working  party on  patient  Information,  comprising 
representatives  from  the  Industry,  consumer  groups,  the  pharmacist 
and  medlclal  professions,  has  been  considering  the  complex  Issue of 
the  provision of  package  Inserts.  Four  meetings  of  the  group  took 
place  several  suggestions  for  the  amendement  of  Articles 6  and  7  of 
Directive  75/319/EEC  resulting  from  the  conclusions of  that  group, 
sl lghtly  amended  to  take  account  of  further  discussions with  Member 
States,  are  set  out  In  the  proposal. 
In  addition,  It  appears  also necessary  to  amend  the  detailed 
requirements  for  the  label I lng  of  medicinal  products. 
It  Is  envisaged  that  the  requirements  for  patient  package  contained 
In  the  directive should  remain  general  In  scope,  and  that  the 
Commission  will  Issue  further  notes  for  guidance  on  t.he  detailed 
preparation of  such  leaflets,  possibly distinguishing  between 
prescription only medicines  and  over-the-counter  products  (OTC). - 9  -
V  CONCLUSIONS 
16  These  three  proposals  have  been  the  subJect  of  several  successive 
rounds  of  consultations,  since  July  1989,  with  the  national 
directors  for  pharmacy  within  the  pharmaceutical  Committee  (July  and 
October  1989),  with  European  associations  representing  the  Interest 
of  pharmaceutical  Industry,  consumer  organizations  and  the  medical 
and  pharmaceutical  profession.  The  objectives  and  content  of  these 
proposals  relating  to  the  national  use of  medicinal  products  seen 
globaly  acceptable  to  the  Interested parties. 
17  In  accordance  with  the  provisions of Articles  SA  and  SC  of  the 
Treaty establishing  the  European  Economic  Community,  the  Commission 
requests  the  Member  States  to  take  the measures  necessary  to  comply 
with  this  package  of  proposals  by  1  January  1992. 
The  Commission  has  taken  Into  account  the  requirements  of  Article ac 
of  the Treaty  and  has  concluded  that  no  special  provision  seems  to 
be  justified at  this stage. 
The  Commission  has  also studied  the  question of  the  high  levels of 
health,  safety,  environmental  and  consumer  protection equlred  by  the 
terms of  Article  100  A,  paragraph  3.  It  has  done  so  following 
consultation of  the  Industrial  and  social  partners  concerned,  and  In 
the  I lght  of  an  analysis of  the  current  technical  capabl lltles of 
the.European  Industry.  The  proposals  take  ful 1  account  of  these 
considerations  In  the  light of  the overal I  objectives of  this 
provision of  the Treaty. - 10  -
Proposal  for  a 
COUNCIL  DIRECTIVE 
on  the wholesale  distribution of medlcl"nal  products  for  human  use 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty  establ lshlng  the  European  Economic 
Community,  and  In  particular Article 100a  thereof, 
Having  regard  to  the  proposal  from  the  Commlsslon<1>, 
In  cooperation with  the  European  Parllament<2>, 
Having  regard  to  the opinion of  the  Economic  and  Social  Commlttee<3>, 
Whereas  It  Is  Important  to adopt  measures  with  the  aim  of  progressively 
establishing  the  Internal  market  over  a  period  expiring on 
31  December  1992;  whereas  the  Internal  market  Is  to comprise  an  area 
without  Internal  frontiers  In  w.hlch  the  free  movement  of  goods,  persons, 
services and  capital  Is  ensured; 
Whereas  the wholesale distribution of medicinal  products  for  human  use 
Is  at  present  subject  to different  provisions  In  the  various  Member 
States;  whereas  many  operations  Involving  the wholesale distribution of 
medicinal  products may  cover  simultaneously several  Member  States; 
( 1 ) 
(2) 
(3) 
/ - 11  -
Whereas  It  Is  necessary  to  exercIse  cont ro I  over  the  entIre  chaIn  of 
distribution  of  medicinal  products,  from  their  manufacture  or  Import 
Into  the  Community  through  to  supply  to  the  public,  so  as  to  guarantee 
that  such  products  are  stored,  transported  and  hand led  In  suItable 
conditions;  Whereas  the  requirements  which  must  be  adopted  for  this 
purpose  will  considerably  faclllte  the  withdrawal  of  defective  products 
from  the  market  and  allow  more  effective  efforts  against  counterfeit 
products; 
Whereas  any  person  Involved  In  the  wholesale  distribution  of  medicinal 
products  should  be  In  possession  of  a  special  authorization;  whereas 
pharmacists and  persons authorized  to supply medicinal  products directly 
to  the  public,  and  who  confine  themselves  to  this  activity,  should  be 
exempt  from  obtaining  this authorization;  Whereas  It  Is  always  necessary 
In  order  to  control  the  complete  chain  of  distribution  of  medicinal 
products,  that  pharmacists  and  persons  authorized  to  deliver  medicinal 
products  to  the  public keep  records showing  entry  transactions. 
Whereas  authorization  must  be  subJect  to  certain  essential  conditions 
and  It  Is  the  responslbll lty  of  the  Member  State  concerned  to  ensure 
that  such  conditions  are  met;  whereas  all  Member  States  must  recognize 
authorizations granted by  other  Member  States, 
HAS  ADOPTED  THIS  DIRECTIVE: - 12  -
Article 1 
1.  This Directive covers  the wholesale  distribution of medicinal 
products  for  human  use  In  the Community. 
2.  For  the  purposes of  this Directive,  the  definition of  "medicinal 
product"  set  out  In  Article  1  of  Council  Directive 65/65/EEc(1) 
shal 1  apply.  In  addition  "wholesale distribution of medicinal 
products"  shal I  mean  alI  activities consisting of  procuring,  holding, 
supplying,  Importing  or  exporting medicinal  products. 
Article 2 
Member  States shal I  take  alI  appropriate action  to ensure  that only 
medicinal  products  In  respect  of  which  a  marketing authorization  has 
been  granted  In  accordance with  Community  law  shall  be  distributed on 
their  territory. 
Article  3 
1.  Member  States shall  take all  appropriate measures  to ensure  that  the 
distribution of  medicinal  products  Is  subJect  to  the  possession of  an 
authorization  to engage  In  activity as  a  wholesaler  In  medicinal 
products. 
2.  Pharmacists  and  persons expressly authorized  to supply medicinal 
products  to  the  public shall  be  exempt  from  obtaining  the 
authorisation  referred  to  In  paragraph  1,  provided  that  they  do  not 
engage,  principally or  secondarl ly,  In  any  activity as wholesaler  of 
medicinal  products. 
(1)  OJ  No  22,  9.2.1965,  p.  369/65. ..;..  13 -
3.  The  possession of  an  authorisation  to  carry out  the  activity of  a 
wholesaler  of  medicinal  products  shal I  not  dispense  from  the 
obligation  to  possess  a  manufacturing  ·authorisation  or  an 
authorisation  for  Importation  from  third  countries  In  accordance 
with  Article  16 of  Council  Directive  75/319/EEcC4>,  and  to  comply 
with  the  conditions  set  out  In  that  respect,  even  when  the 
manufacturing activity  Is  secondary. 
4.  A  I I  Member  States  sha II  draw  up  a  I I  st'  of  the  persons  whIch  1  t  has 
authorized  to  engage  In  the  activity  of  wholesaler  In  medicinal 
-~roducts.  It  shal I  send  this  I 1st,  and  details of  ~ny changes  to  It, 
to the other  Member  States and  to  the Commission. 
5.  Checks  on  the  persons  and  establishments  authorized  to  engage  In  the 
activity  of  wholesaler  In  medicinal  products  and  the  Inspection  of 
their  premises  shall  be  carried  out  under  the  responsibility  of  the 
Member  State which  granted  the authorization. 
6.  The  Member  State  which  granted  the  authorization  referred  to  In 
paragraph  1  shall. suspend  or  revoke  this  authorization  If  the 
conditions  of  authorization  cease· to  be  met.  It  shall  forthwith 
Inform  the other Member  States and  the Commission  thereof. 
7.  If  a  Member  State  considers  that,  In  respect  of  a  person  holding  an 
authorIzatIon  granted  by  another  Member  State  under  the  terms  of 
paragraph  1,  the  conditions of  authorization are not  or  are no  longer 
met,  It  shall  lmme·dlately  Inform  the  Commission  arid  the  other  Member 
State  Involved.  The  latter  shall  take  the  measures  necessary  and 
Inform  the  Commission  and  the  first  Member  State  of  the  decisions 
taken  and  the  reasons  for  these decisions. 
(4)  OJ  No  l  147,  9.6.1975,  p.  13. -. 14  -
Article 4 
1.  Member  States shall  ensure  that  the  time  taken  for  the  procedure  for 
granting  the  authorization  referred  to  In  Article  3(1)  does  not 
exceed  90  days  from  the  day  on  whIch  the  competent  authorIty  of  the 
Member  State concerned  receives  the  appl lcatlon. 
2.  All  decisions  to  refuse,  suspend or  revoke  the  authorization  referred 
to  In  Article  3(1)  shal I  state  In  detail  the  reasons  on  which  they 
are  based.  A decision  shall  be  notified  to  the  party  concerned  who 
shall  at  the  same  time  be  Informed  of  the  remedies  aval lable  to  him 
under  the  laws  In  force  and  of  the  t lme  limit  allowed  for  the 
exercise of  such  remedies. 
Article 5 
In  order  to  obtain  the  authorization  referred  to  In  Article 3(1), 
appl !cants must  fulfl I  the  following  minimum  requirements: 
(a)  they  must  have  suitable  and  adequate  premises,  such  as  to  ensure 
good  conservation of  the medicinal  products warehoused; 
(b)  they must  have  a  qualified personnel  meeting  the conditions  provided 
for  by  the  legislation of  the Member  State concerned; 
(c)  they  must  undertake  to  fulfil  the  obligations  Incumbent  on  them 
under  the  terms  of  Article 6. 
Article 6 
Holders  of  the  authorization  referred  to  In  Article 3(1)  shal 1  be 
requl red: 
(a)  to  make  the  premises  referred  to  In  Article 5(a)  accessible  at  all 
times  to  the persons  responsible  for  Inspecting  them; - 15  -
(b)  to  obtain  medicinal  products  only  from  persons  who  are 
themselves  In  possession  of  the  authorization  referred  to  In 
Article 3(1)  or  who  are exempt  from  obtaining this authorization 
under  the  terms  of Article 3(2); 
(c) .to .supply  medicinal  products  only  to  persons  who  are  themselves  In 
possession  of  the  authorization  referred  to  In  Article  3(1)  or  who 
are  exempt  from  obtaining  this  author lzat lon ·under· the  terms  of 
Article 3(2); 
(d)  to  have  an  emergency  plan  which  allows  participation  In  any  action 
of  withdrawal  from  the  market  ordered  by  the  competent  authorities 
or  Initiated  by  the manufacturer  of  the medicinal  product  concerned; 
(e)  to  keep  detailed  records, possibly  computerised,  stating  for  each 
transaction  In  medicinal  products  received  or  dispatched,  the 
following  Information: 
- date, 
-name of  the medicinal  product, 
-production batch  number, 
-quantity received or  suppl led, 
- name  and  address of  the supplier  or  consignee; 
when  the  delivery  Is  destined  for  a  retailer,  the  production  batch 
number  Is  not  required; 
(f)  to  carry  out,  at  least  once  a  year,  an  exact  check  on  the  records 
referred  to  under  (e),  comparlng·the  list  of  products  received  and 
dispatched  with  the  products  In  stock  and  Indicating  any 
discrepancies  In  a  report; 
(g)  to  keep  the  records  referred  to  under  (e)  and  the  reports  referred 
to under  (f)  available  to  the  competent  authorities,  for  Inspection 
purposes,  for  a  period of  three years; - 16  -
Article 7 
With  regard  to  the  supply  of  medicinal  products  to  pharmacists  and 
persons  author I  zed  to  supply  medicinal  products  to  the  public,  Member 
States shall  not  Impose  upon  the  holder  of  an  authorization  referred  to 
In  Article 3(1},  which  has  been  granted  by  another  Member  State,  any 
obligation  stricter  than  those  they  Impose  on  persons  which  they  have 
themselves  authorized  to carry out  equivalent  activities. 
Article 8 
1.  All  pharmacists,  as  well  as  all  persons  authorized  to  supply 
medicinal  products  to  the  public,  shall  be  requ!red  to  keep  accurate 
records,  possibly  computerised,  giving  the  following  details at  least 
for  each  transaction of  medicinal  products  received: 
- date 
-name and  pharmaceutical  form  of  the  medicinal  product, 
-quantity received, 
-name and  address of  the supplier. 
2.  The  records  referred  to  In  paragraph  1  shall  be  kept  available  to  the 
competent  authorities,  for  Inspection purposes,  for  a  period of  three 
years. 
Article 9 
This·  Directive  shall  not  prevent  the  application  of  stricter 
requirements  laid  down  by  Member  States  In  respect  of  the  supply  of 
medicinal  products  to  the public on  their  territory. - 17 -
Article 10 
If  appropriate,  the  Commission  shall  publish  guidelines  on  good 
distribution  practices.  In  that  case  the  pharmaceutical  committee 
1  nst I tu  ted  by  Counc I I  DecIsIon  75/320/EEc<5 > sha I I  be  consu I ted. 
Article  11 
Member  States  shall  take  the  measures  necessary  to  comply  with  this 
Directive  before 
Commission  thereof. 
January  1992.  They  shall  forthwith  Inform  the 
The  provisions  adopted  pursuant  to  the  first  paragraph  shall  make 
express  reference  to this Directive. 
Article  12 
This Directive  Is  addressed  to  the  Uember  States. 
Done  at  Brussels  For  the Counc I I 
( 5)  OJ  No  L  147,  9.  6. 1975,  p.  23. - 18  -
Proposal  for  a 
COUNCIL  DIRECTIVE 
concerning  the  legal  status for  the  supply 
of medicinal  products  for  human  use 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES 
Having  regard  to  the Treaty establ lshlng  the  European  Economic  Community 
and  In  particular Article  100a  thereof, 
Having  regard  to  the proposal  from  the  Commlsslon<1>, 
In  cooperation with  the  European  Parllament<2>, 
Having  regard  to  the opinion of  the  Economic  and  Social  Commlttee<3>, 
Whereas  measures  aimed  at  progressively establishing  the  Internal  market 
during  the  period up  to  31  December  1992  need  to be  taken;  whereas  the 
Internal  market  Is  to comprise  an  area without  Internal  frontiers  In 
which  the  free movement  of  goods,  persons,  services  and  capital  Is 
ensured; 
Whereas  the  conditions  for  supply of medicines  for  human  use  to  the 
publ lc  vary  appreciably  from  one  Member  State to  the  another;  whereas 
medicines on  free sale  In  certain Member  States can  only  be  obtained 
only on  medical  prescription  In  other  Member  States; 
(1) 
(2) 
(3) - 19  -
Whereas  under  the  terms of  Council  Directive  (4),  the 
advertising and  promotion  to  the  general  publ lc of  medicinal  products 
which  are only  aval table on  prescription  Is  prohibited;  whereas,  In  view 
of  the  development  of means  of  communication,  the conditions of  del Ivery 
of  medicinal  products  to  the  pub I lc  should be  harmonized; 
Whereas,  moreover,  persons moving  around  within  the Community  have  the 
right  to carry  a  reasonable quantity of  medicinal  products  legitimately 
obtained  for  their  personal  use;  whereas  It must  also be  possible  for  a 
person establ !shed  In  one  Member  State  to  receive  from  another  Member 
State a  reasonable quantity of medicinal  p~oducts  Intended  for  his 
personal  use;  whereas  It  Is  Important  therefore  to harmonize  the 
conditions of  delivery of  medicinal  products  to the  publ lc; 
Whereas,  In  addition,  under  the  new  system of  registration of medicinal 
products  In  the Community,  ~ertaln medicinal  products will  be  the 
subject of  a  Community  marketing  authorization;  In  this context,  the 
legal  status  for  the  supply of medicinal  products  covered  by  a  Community 
marketing authorization needs  to be  fixed;  whereas,  It  Is  Important  to 
fix  the criteria on  basis of  which  Community  decisions  wl  I I  be  taken; 
Whereas  It  Is  therefore appropriate,  In  a  first  stage,  to harmonize  the 
basic principles appl lcable  to  the  legal  status for  the supply of 
medicinal  products  In  the Community  or  In  the Member  State concerned, 
whl le  taking  as  a  starting point  the  the  principles already establ !shed 
on  this subject  by  the Councl I of  Europe  as  wei l  as  the work  of 
harmonisation  completed  within  the  framework  of  the  United  Nations, 
concerning  narcotics  and  psychotroplcs, 
HAS  ADOPTED  THIS  DIRECTIVE: 
(4) -·  20  -
Article  1 
1.  This  Directive concerns  the  legal  status for  the  supply of medicinal 
products  for  human  use  In  the  Community. 
2.  For  the  purpose  of  this Council  Directive,  the  definition of. 
"medicinal  product"  In  Article  1  of  Councl I  Directive 65/65/EEc(1) 
sha I I  app 1  y. 
In addition, 
-"legal status  for  supply"  shal I  mean  :  the conditions  under  which  a 
medicinal  product  may  be  supplied  to  the  public, 
-"medical  prescription"  shal I mean  :  any  prescription emanating  from 
a  doctor  qual I fled  to prescribe medicinal  products  In  the Community 
or  from  a  health  professional  qualified  to prescribe medicinal 
products  under  the  terms  of  the  legislation of  the Member  State 
where  the medicinal  product  Is  del lvered. 
Article  2 
Medicinal  products which  may  only  be  aval !able on  medical  prescription 
shal 1  be  classified,  at  the  time  of  granting  the  authorization  for 
marketing,  In  one  of  the  fol lowlr.g  categories  : 
a)  medicinal  products on  prescription.  which  may  be  renewed  during  a 
period of  six months  from  the  date of  the prescription,  unless 
otherwise specified; 
b)  medicinal  products on  prescription,  which  may  not  be  renewed 
without  the  prescriber's express consent; 
c)  medicinal  products on  special  prescription,  containing a  substance 
classified as  a  psychotropic or  a  narcotic substance within  the 
meaning  of  the  International  conventions  In  force  (conventions of 
the  United  Nations of  1961  and  1971); 
d)  medicinal  products on  restricted prescription,  reserved 
- for  use  In  hospitals, 
-to certain specialists. 
(1}  OJ  No  22,  9.2.1965,  p.  369/65. ..,  21  -
Article 3 
1.  When  a  marketing  authorization  Is  granted,  the  competent  authority 
shal 1  specJfy  the  legal  status for  the  supply of  the medicinal 
product: 
-medicinal  product  not subJect  to medical  prescription, 
-medicinal  product  subject  to medical  prescription,  mentioning one 
of  the  categories  referred  to  In  Article 2. 
To  this end,  the criteria  laid  down  In  Article 4  shal I  apply. 
2.  All  medical  products containing a  new  chemical  entity shall  be 
subJect  to medical  prescription,  and  classed  In  one of  the categories 
referred  to  In  Article 2. 
3.  The  competent  authoritY. shal I  pub! Ish  at  least  annually  the  I Jst  of 
medicinal  products  subJect  to medical  prescription,  specifying  the 
category of  classification. 
4.  On  the occasion of  the 5-yearly  renewal  of  the marketing 
authorisation or  when  new  scientific elements are communicated  to 
them,  the  competent  authorities shal I  examine  and,  as  appropriate, 
may  amend  the  legal  status  for  the  supply of  a  medicinal  products,  by 
applying  the criteria  listed  In  Article  4. 
Article 4 
1.  Medicinal  products which  contain  substances which  are  1 lkely  to 
present  a  direct or  Indirect  danger  to  human  health.  even  under 
normal  conditions of  use,  shall  not  be  suppl led  to  the publ lc without 
medical  prescription.  The  following criteria shal I  be  taken  Into 
consideration  In  this  respect  : - 22  -
a)  potential  risks  appearing  during  the preclinical  and  clinical 
tests and  trials, 
b)  novelty of  the active principle,  as  stated  In  Article 3, 
paragraph  2, 
c)  possibility of  serious side effects  In  normal  conditions of  use 
d)  serious risks associated with  contra-Indications and  precautions 
for  use 
e)  Indications  requiring a  medical  diagnosis or  special  medical 
supervision 
f)  harmfulness of constituents under  normal  conditions of use,  taking 
Into  account  posology,  pack  size or  possible excessively extended 
treatment; 
g)  parenteral  administration,  except  when  very  long  term  II  lness 
requires  an  active participation by  the patient  In  the  treatment 
(for  example:  diabetes) 
h)  Important  risk of  abuse,  addiction or  misuse  for  criminal 
purposes, 
2.  Moreover,  medical  products which  may  be  aval lable without 
prescription shal I  show  a  substantial  safety  In  use  In  the  treatment 
of  minor  al lments  or  symptoms,  usually  capable of  rapid  and 
spontaneous  relief,  which  are easily  Identifiable by  users  and  do  not 
Justify a  medical  consultation. 
i 
\ 
\ 
I 
\ 
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Article 5 
1.  Within  two  years of  adoption of  this Directive,  the Member  States 
shal I  communicate  to the  Commission  and  to  the other  Member  States, 
the  I 1st  of  medicines  which  are  aval lable only  on  medical 
prescription on  their  territory,  mentioning  the  category of 
classification. 
2.  Each  year,  Member  States shal I  communicate  to  the Commission  and  to 
the other  Member  States  the  changes  that  have  been  made  to  the  list 
referred to in paragraph  1. 
3.  Within  four  years of adoption of  this Directive,  the  Commission  shal I 
submit  a  report  to  the Councl I on  the  appl lcatlon of  this Directive. 
This  report  wl  I I  be  accompanied,  If  necessary,  by  appropriate 
proposals. 
Article 6 
Member  States shall  take  the measures  necessary  to comply  with  this 
Directive  before  1  January  1992.  They  shall  forthwith  Inform  the 
Commission  thereof. 
The  provisions  adopted  pursuant  to  the first  paragraph  shal 1 make 
express  reference  to this Directive. 
Article 7 
This Directive  Is  adressed  to  the Member  States. 
Done  at  Brussels  For  the Counc I 1 - 24  -
Proposal  for  a 
COUNCIL  DIRECTIVE 
on  the  label I lng  of  medicinal  products  for  human  use 
and  on  package  leaflets 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the Treaty establ lshlng  the  European  Economic  Community 
and  In  particular Article  100a  thereof, 
Having  regard  to  the  proposal  from  the Commlsslon<1>, 
In  cooperation with  the  European  Pari lament<2>, 
Having  regard  to  the opinion of  the  Economic  and  Social  Commlttee<3>, 
Whereas  measures  aimed  at  progressively establ lshlng  the  Internal  market 
during  the  period up  to  31  December  1992  need  to be  taken;  whereas  the 
internal  market  Is  to  comprise  an  area without  Internal  frontiers  In 
which  the  free  movement  of  goods,  persons,  services and  capital  Is 
ensured; 
Whereas  Councl I  Directive 65/65/EEC  of  26  January  1965  on  the 
approximation of  provisions  laid  down  by  law,  regulation or 
administrative action  relating  to medicinal  products<4>,  as  last 
amended  by  Directive 89/341/EEc<5>,  establishes a  list of 
(1) 
(2) 
(3) 
(4)  OJ  No  22,  9.2.1965,  p.  369/65. 
(5)  OJ  No  L 142,  25.5.1989,  p.  11. - 25  -
particulars  to  be  given on  the  Immediate  packaging  and 'the outer 
packaging  of medicinal  products  for  human  use;  whereas  this  I 1st  should 
be  supplemented  and  detal Is  given  of  how  label I lng  Is  to  be  presented; 
Whereas  the Second  Councl I  Directive 75/319/EEC  of  20  May  1975  on  the 
approximation of  provisions  laid  down  by  law,  regulation or 
administrative action  relating  to proprietary medicinal  products<S),  as 
last  amended  by  Directive 89/341/EEC,  establishes a  non-Inclusive  list 
of  particulars to be  Included  In  package  Insert  leaflets;  whereas  this 
I 1st  should be  supplemented  and  detal Is  given of  how  such  leaflets are 
to be  presented; 
Whereas  the  provisions on  label I lng  and  on  package  Insert  leaflets 
should  be  united  In  a  single  legislative text; 
Whereas  the  provisions governing  the  Information  suppl led  to users 
should  provide  a  high  degree of  consumer  protection,  In  order  that 
medicinal  products  be  used  correctly on  the basis of  complete  and 
comprehensive  Information; 
Whereas  the  marketing of  medicinal  products whose  label I lng  and  package 
leaflets comply  with  the  provisions of  this Directive  should  not  be 
prohibited or  Impeded  on  grounds  connected  with  the  label 1  lng  or  package 
leaflet, 
HAS  ADOPTED  THIS  DIRECTIVE: 
(6)  OJ  No  L 147,  9.6.1975,  p.  13. 
\ 
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Chapter  I 
Scope  and  definitions 
Article 1 
1.  This  Directive deals with  the  labelling of  medicinal  products  for 
human  use  and  leaflets  Inserted  In  packages  of  such  products. 
2.  For  the  purposes of  this Directive,  the definition of  "medicinal 
product"  laid  down  In  Article 1 of  Directive 65/65/EEC  shal 1  apply. 
In  addition  to  this, 
- •name  of  the medicinal  product•  shal I  mean  the  name  given  to a 
medicinal  product,  which  may  be  an  Invented  name,  a  common  name 
together  with  a  trademark  or  the  name  of  the manufacturer,  or  a 
scientific name  together  with  a  trade mark  or  the  name  of  the 
manufacturer; 
- •conrnon  name•  shall  mean  the  International  non-proprietary  name 
recommended  by  the World  Health  Organization,  or,  If  one  does  not 
exist,  the usual  common  name; 
- •Immediate  packaging•  shal I  mean  the  container or  other  form  of 
packaging  Immediately  In  contact  with  the medicinal  product; 
- •outer  packaging•  shal I  mean  the  packaging  Into which  Is  placed  the 
Immediate  packaging; 
- •package  leaflet• shal I mean  a  leaflet  containing  Information  for 
the user  which  accompanies  the medicinal  product  to which  It 
refers. 
Article 2 
No  part of  this Directive shall  be  taken  to authorize  the marketing of  a 
medicinal  product  for  which  an  authorization  In  accordance with 
Community  legislation has  not  been  Issued. - 27  -
Chapter  II 
Labelling of  medl~lna·l  products 
Article  3 
The  following  particulars shal I  appear  on  the outer  packaging of 
medicinal  products or,  where  there  Is  no  outer  packaging,  on  the 
Immediate  packaging. 
a)  the  name  of  the medicinal  product,  Including or  followed  by  the 
common  name  If  the  product  contains only  one  active  Ingredient; 
b)  a  statement  of  the  active  Ingredients expressed  qual ltatlvely and 
quantitatively per  dosage  unit or  according  to the  form  of 
administration  for  a  given  volume  or  weight,  using  their  common 
names;. 
c)  the  pharmaceutical  form  and  the contents  by  weight,  by  volume  or 
number  of  doses of  the  product; 
d)  a  I 1st of  the exclplents, 
e)  the  route  and  method  of  administration; 
f)  a  special  warning  that.the product  must  be  stored out  of  reach.of 
children; 
g)  the expiry  date  In  clear  terms  (month/year), 
h)  special  storage  precautions,  If  any; 
:.:.  _) - 28  -
I)  special  precautions  for  disposal  of  unused  medicinal  products or 
waste materials derived  from  such  products,  If  appropriate; 
J)  the  name  and  address of  the  person  responsible  for  placing  the 
medicinal  product  on  the  market  and,  where  different, of  the 
manufacturer; 
k)  the  number  of  the  authorization  to put  the medicinal  product  on  the 
market; 
I)  the manufacturer's  batch  number. 
Article 4 
1.  The  following  particulars shall  appear  on  Immediate  packaglngs  placed 
In  an  outer  packaging  which  complies with  the  reQuirements  laid down 
In  Article  3: 
-name of  the medicinal  product; 
-Quantity of  active constituents,  using  common  names; 
-route and  method  of  administration; 
-expiry date; 
-batch number. 
2.  Paragraph  1 shall  not  apply  to  Immediate  packaglngs  containing a 
single dose  which  are  too small  to carry all  the particulars  listed 
In  paragraph  1. ,_-;: 
- 29  -
Article 5 
1.  The  particulars referred  to  In  Articles  3  and  4  shal I  be  easl ly 
visible,  clearly comprehensible  and  lndel lble. 
2.  The  particulars  I lsted  In  Article 3(a)  to (f)  on  the one  hand,  and 
(g)  to  (I)  on  the other  hand,  shall  as  far  as possible  appear  In  the 
same  field of  vision. 
3.  The  particulars  listed  In  Article 3  shall  appear  In  the official 
language  or  languages of  the Member  State  where  the  product  Is  put 
on  the market.  This provision shal I  not  prevent  these  particulars 
from  being  Indicated  In  various  languages,  provided  the  Information 
given  Is  the  same  In  all  languages  used. 
Article 6 
1.  Member  States shall  not  prohibit or  Impede  the  placing on  the market 
of  medicinal  products within  their  territory on  the  grounds  that  the 
labelling  Is  Incorrect,  If  such  labelling complies  with  this 
Chapter. 
2.  Notwithstanding  paragraph  1,  Member  States may  require  the  following 
Information  to be  provided on  the outer  packaging or,  In  the  absence 
of  such,  on  the  Immediate  packaging: 
-price of  the medicinal  product, 
-reimbursement  conditions  by  social  security organisations, 
-the  legal  status  for  supply  to  the patient,  particularly where  a 
new  medicinal  product  Is  concerned. - 30  -
Chapter  Ill 
User  leaflet 
Article 7 
The  Inclusion  In  the  packaging  of  medicinal  products of  a  package 
leaflet  for  the  Information of users shal I  be  obi lgatory  unless alI  the 
Information  required  by  Article 8  Is directly conveyed  on  the outer 
packaging or  on  the  Immediate  packaging. 
Article 8 
1.  The  leaflet  shall  Include,  usually  In  the  following order: 
a)  for  the  Identification of  the medicinal  product: 
-name of  the  medicinal  product, 
-quantitative and  qualitative composition  In  terms  of  active 
Ingredients,  using  the  common  names, 
-pharmaco-therapeutic group,  If  there exists a  term  easl ly 
comprehensible  for  the  patient, 
-name and  address  of  the  holder  of  the marketing authorization, 
and,  where  different,  of  the manufacturer; 
b)  the  therapeutic  Indications; 
c)  a  list of  Information which  Is  useful  before  taking  a  medicinal 
product: 
-contra-Indications, 
-appropriate precautions  for  use, 
- Interactions with other medicinal  products  and  other  forms  of 
Interaction  (for  example,  alcohol,  tobacco)  which  may  affect  the 
use of  the medicine, 
- special  warnings, - 31 
thIs  I I  st must  : 
- take  Into account  the particular  condition of  certain categories 
of users  (e.g.  children,  pregnant  or  breastfeedlng  women,  the 
elderly,  persons with specific pathological  conditions), 
-mention,  If  appropriate,  potential  effects on  the ability to 
drive  vehicles or  to operate machinery; 
- refer  to  the exclplents knowledge  of  which  Is  Important  for  a 
safe and  effective use of  the medicinal  product; 
d)  the  necessary  Instructions  for  proper  use,. In  particular 
-the usual  dose  and  the  maximum  dose, 
-the method  and  route of  administration, 
- the  frequency  of administration,  specifying  If  necessary  the 
appropriate  time  at  which  the medicinal  product  should or  must 
be  administered; 
and,  as appropriate,  depending  on  the  nature of  the  product 
-the duration of  treatment,  when  It  should  be  I lmlted, 
-the action  to undertake  In  the  case of  overdose  (symptoms, 
emergency  procedures.  antidotes), 
-the course of  action  to  take when  a  dosa has  not  been  taken, 
- the  way  the  treatment  should  stopped,  If  stopping  the  treatment 
may  lead  to withdrawal  effects; 
e)  a  description of 
the  undesirable effects which  can  occur  under  normal  use of  the 
medicinal  product,  with  Indication  If  possible of  their 
Importance,  and  If  necessary  the action  to be  taken  In  such  case; 
when  the medicinal  product  Is  new,  the patient  should  be  expressly 
Invited  to communicate  any  undesirable effect which  Is  not 
mentlonned  In  the  leaflet  to his doctor  or  to his  pharmacist; 
f)  a  reference  to the expiry  date  Indicated on  the  label,  with 
- a  warning  against  using  the  product  after  this date, 
-where appropriate,  special  storage  precautions, 
- If  necessary  a  warning  against  visible signs of  deterioration, - 32  -
g)  alI  other  Information  compatible with  the  summary  of  product 
characteristics of  the product,  useful  for  health education,  and 
on  condition  that  It  Is  not  of  a  promotional  nature. 
2.  Notwithstanding point  1  b),  the  competent authorities may  decide  that 
certain therapeutic  Indications  wl  I I  not  be  mentlonned  In  the  package 
jeaflet, when  the  dissemination of  such  Information might  have 
serious disadvantages  for  the patient. 
3.  The  leaflet  may  Include  symbols· or  plctograms  designed  to elaborate 
certain  Information mentlonned  In  paragraph  1, 
Article 9 
The  package  leaflet  must  be  written  In  clear  and  understandable  terms 
for  the patient,  In  the official  language  or  languages of  the Uember 
State where  the medicinal  product  Is  put  on  the market.  This  provision 
does  not  prevent  the  leaflet  being  printed  In  several  languages, 
provided  that  the  same  Information  Is  given  In  all  the  languages  used. 
Article 10 
uember  States shall  not  prohibit  or  Impede  the placing on  the market  of 
medicinal  products within  their  territory on  the grounds  that  the 
package  leaflet isnrt correct,  If  the  package  leaflet  compl les with  this 
Chapter. - 33 -
Chapter  IV 
General  and  final  provisions 
Article  11 
1.  One  or  more  specimens  or  mock-ups  of  the outer  packaging  and  the 
Immediate  packaging of  a  medicinal  product,  together  with  the  draft 
package  leaflet,  shal I  be  submitted  to  the  competent  authorities of 
the  Member  State concerned. 
2.  AI  1  proposed  modifications  to  the outer  packaging,  to the  Immediate 
packaging or  to  the  package  leaflet  shal I  be  submitted  to the 
competent  authorities of  the  Member  State concerned.  If  the  competent 
authorities  have  not  opposed  a  draft  modification within 90  days 
following  the  Introduction of  the  request,  the  appl lcant  may  proceed 
to put  the modification  Into effect. 
3.  The  competent  authorities shal I  notal low·a  medicinal  product  to be 
placed on  the  market,  If  the  packaging or  the  package  leaflet  do  not 
comply  with  the  provisions of  this Directive or  If  they  are  not 
compatible with  the  particulars  listed  In  the  summary  of  the  product 
characteristics referred  to  In  Article 4b  of  Directive 65/65/EEC. 
4.  The  fact  that  the  competent  authorities do  not  refuse  a  marketing 
authorization  for  a  reason  associated with  the  labelling or  the 
package  Insert,  does  not  alter  the  general  legal  I labl I lty of  the 
manufacturer  or  as  approplate  the  marketing  authorization holder. - 34  -
Artlcla 12 
1.  When  the  provisions of  this Directive are  not  observed,  and  an  order 
addressed  to  the  person concerned  has  remained  without  effect,  the 
competent  authorities of  a  Member  State may  suspend  or  revoke  the 
authorization  to place  the medicinal  product  on  the market,  until  the 
label I lng  and  leaflet of  the medicinal  product  In  question  has 
compl led  with  the  requirements of  this Directive. 
2.  AI  I  decisions  taken  pursuant  to paragraph  1 shal I  state  In  detal 1  the 
reasons on  which  they  are  based.  They  shall  be  notified  to  the  party 
concerned,  who  shall  at  the  same  time  be  Informed  of  the  remedies 
available  to  him  under  the  laws  In  force  and  of  the  time  limit 
allowed  for  the exercise of  such  remedies. 
Article  13 
As  necessary,  the  Commission  shal I  publIsh  guldel Jnes  concerning: 
-the formulation of  certain warnings  for  certain categories of 
medicinal  products; 
-the particular  Information  needs  relative  to self-medication; 
-the readabl llty of  particulars on  the  label I lng  and  leaflet; 
-utilization of  bar  codes  for  the  Identification of medicinal 
products. 
For  this purpose,  the Commission  shal I  consult  the Committee  for 
Proprietary Medicinal  Products  Instituted by  Directive 75/319/EEC. - 35  -
Article 14 
1.  Articles  13  to  20  of  Directive 65/65/EEC  and  Articles 6  and  7  of 
Directive 75/319/EEC  are  hereby  repealed. 
2.  References  made  to provisions which  have  been  repealed shal I  be 
understood  to  refer  to  the  present  Directive,  In  accordance  with  the 
table of  concordance  given  In  the  Annex. 
Article  15 
1.  Member  States shal I  take  the  measures  necessary  to comply  with  this 
Directive  before  1  January  1992.  They  shal I  forthwith  Inform  the 
Commission  thereof. 
The  provisions  adopted  pursuant  to  the  first  subparagraph  shal I  make 
express  reference  to  this Directive. 
2.  From  1  January  1993,  Member  States shall  refuse  an  appl lcatlon  for 
marketing authorisation or  for  the  renewal  of  an  existing 
authorisation,  when  the  label I lng  and  the  leaflet  do  not  conform  to 
the  requirements of  this Directive. 
Article  16 
This  Directive  Is  addressed  to  the  Member  States. 
Done  at  Brussels  For  the  Counc I I - 36  -
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COMPETITIVENESS  AND  EMPLOYMENT  IMPACT  STATEMENT 
relating  to  the  proposals 
for  a  rational  use of  medicines 
I.  What  Is  the main  reason  for  Introducing  the measures? 
Completion of  the  Internal  market;  Improvement  of  the  protection of 
pub! lc  health;  promotion  of  a  rational  use  of  medicinal  products; 
consumer  Information. 
11.  Features of  the  businesses  In  question 
The  measures  Involve  pharmaceutical  manufacturers  as  wei 1  as 
wholesalers  In  medicinal  products. 
Because  of  the  high  costs of  developing  new  products, 
pharmaceutical  enterprises are often  large  companies  (multinational 
or  national).  There  are,  however,  some  smaller  and  medium  sized 
manufacturers geared  at  the  national  market. 
Distribution  companies  (wholesalers)  are generally  large  sized 
companies,  following  restructuratlon operations  and  mergers  In  the 
past  ten  years. 
Ill. What  direct obligations does  this measure  Impose  on businesses? 
Manufacturers of medicinal  products 
-obi lgatlon  to conform with  new  regulations  on  Iabeii lng  and 
package  leaflets  :  many  companies  are already adapting  their 
Iabeii lng - 43  -
and  package  leaflets  to  the principles proposed  (no additional 
costs  for  businesses  - economies  of  scales  stemming  from  the 
harmonisation of  rules on  label ling  and  package  leaflets). 
Wholesalers  In  medicinal  products 
-obi lgatlon  to  have  appropriate  premises  and  a  qual I fled 
personnel  :  this obi lgatlon  Is  already  laid  down  In  most  Member 
States  and  Is  necessary  In  order  to guarantee  the  safety  and 
Identity of  medicinal  products  distributed; 
-obi lgatlon  to maintain  distribution  records  and  to verify  them 
every  year  :  this  provision should  allow  to  trace  batches of 
medicinal  products  through  the distribution chain  and  facilitate 
recal I  operations  In  the  case of  accidents,  as  wet 1  as  the 
struggle against  counterfeiting. 
IV.  What  Indirect obligations are  local  authorities  likely  to  Impose  on 
businesses  7 
None  foreseen. 
V.  Are  there  any  special  measures  In  respect of  SMEs  7 
No. II 
- 44  -
VI.  What  Is  the  likely effect on 
a)  tho  competitiveness of business  7 
The  proposed  measures  wl  I I  facf I I tate marketing,  communication 
and  distribution  through  the  Internal  frontiers of  the 
Community.  Some  companies  wl  I I  thus  have  to  make  efforts  In 
order  to  maintain  their  competitiveness  vis-A-vis  companies 
establ !shed  elsewhere  In  the  Community. 
b)  employment  7 
No  significant  effect  Is  anticipated. 
VII.  H<lvo  both  sldtl::>  of  Industry  boon  consulted on  tho::>o  proposals  7 
Following  Interested parties were  consulted  : 
associations of  the  pharmaceutical  Industry, 
-associations of  wholesalers  In  medicinal  products, 
-associations ot consumers, 
associations of  pharmacists, 
associ at Ions  of  doctors  and  other  hca I th  professionals. ISSN 0254-1475 
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